SKYRIZI (Abbvie Pty Ltd)
Product name
SKYRIZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
Risankizumab
Registration type
EOI
Indication
Ulcerative Colitis
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.